急性髓细胞白血病的新药治疗

[1]	Stone RM,Mandrekar SJ,Sanford BL et al.Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation[J].N Engl J Med,2017,377:454-464.
[2]	Aziz H,Ping CY,Alias H,et al.Gene mutations as emerging biomarkers and therapeutic targets for relapsed acute myeloid leukemia[J].Front Pharmacol,2017,8:897.
[3]	Dang L,Su SM.Isocitrate dehydrogenase mutation and (R)-2-hydroxyglutarate:from basic discovery to therapeutics development[J].Annu Rev Biochem,2017,86:305-331.
[4]	Ragon BK,DiNardo CD.Targeting IDH1 and IDH2 mutations in acute myeloid leukemia[J].Curr Hematol Malig Rep,2017,12:537-546.
[5]	Stein EM,DiNardo CD,Pollyea DA,et al.Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia[J].Blood,2017,130:722-731.
[6]	DiNardo CD,Stein EM,de Botton S,et al.Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML[J].N Engl J Med,2018,378:2386-2398.
[7]	DiNardo CD,Pratz K,Pullarkat V,et al,Venetoclax combined with decitabine or azacitidine in treatment-naive,elderly patients with acute myeloid leukemia[J].Blood,2019,133:7-17.
[8]	Mei M,Aldoss I,Marcucci G,et al.Hypomethylating agents in combination with venetoclax for acute myeloid leukemia:Update on clinical trial data and practical considerations for use[J].Am J Hematol,2019,94:358-362.
[9]	DiNardo CD,Rausch CR,Benton C,et al.Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies[J].Am J Hematol,2018,93:401-407.
[10]	DiNardo CD,Pratz KW,Letai A,et al.Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia:a non-randomised,open-label,phase 1b study[J].Lancet Oncol,2018,19:216-228.
[11]	Stein EM,DiNardo CD,Fathi AT,et al.Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib[J].Blood,2019,133:676-687.
[12]	Castaigne S,Pautas C,Terré C,et al.Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701):a randomised,open-label,phase 3 study[J].Lancet,2012,379:1508-1516.
[13]	Hills RK,Castaigne S,Appelbaum FR,et al.Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia:a meta-analysis of individual patient data from randomised controlled trials[J].Lancet Oncol,2014,15:986-996.
[14]	Döhner H,Weisdorf DJ,Bloomfield CD.Acute myeloid leukemia[J].N Engl J Med,2015,373:1136-1152.